Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 004890109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
RA Capital Management, L.P.
13D/A
|
28.8% |
4/23/2026
Event 4/22/2026
|
||
| RA Capital Management, L.P. | 28.8% | |||
| Peter Kolchinsky | 28.8% | |||
| Rajeev Shah | 28.8% | |||
| RA Capital Healthcare Fund, L.P. | 27.7% | |||
|
Sands Capital Life Sciences Pulse Fund II, L.P.
13G/A
|
5.3% |
8/13/2026
Event 6/30/2026
|
||
| Sands Capital Life Sciences Pulse Fund II, L.P. | 5.3% | |||
| Sands Capital Alternatives, LLC | 5.3% | |||
| Sands Frank M. | 5.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Citadel Advisors LLC
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Citadel Advisors LLC | 0% | |||
| Citadel Advisors Holdings LP | 0% | |||
| Citadel GP LLC | 0% | |||
| Citadel Securities LLC | 0% | |||
| Citadel Securities Group LP | 0% | |||
| Citadel Securities GP LLC | 0% | |||
| Kenneth Griffin | 0% | |||
|
Perceptive Advisors LLC
13G/A
|
0% |
6/4/2025
Event 6/2/2025
|
||
| Perceptive Advisors LLC | 0% | |||
| Joseph Edelman | 0% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 46 | 21.4 M | $38.1 M |
| 2026 Q1 | 44 | 16.2 M | $22.6 M |
| 2025 Q4 | 48 | 18.6 M | $44.9 M |
| 2025 Q3 | 49 | 17.5 M | $32.7 M |
| 2025 Q2 | 55 | 17.8 M | $21.2 M |
| 2025 Q1 | 64 | 22.5 M | $45.7 M |
| 2024 Q4 | 65 | 23.7 M | $142 M |
| 2024 Q3 | 58 | 23.1 M | $162 M |
| 2024 Q2 | 59 | 23.5 M | $136 M |
| 2024 Q1 | 52 | 15.3 M | $109 M |
| 2023 Q4 | 45 | 15.4 M | $74.8 M |
| 2023 Q3 | 46 | 15.1 M | $144 M |
| 2023 Q2 | 41 | 15.1 M | $196 M |
| 2023 Q1 | 41 | 15.2 M | $191 M |
| 2022 Q4 | 19 | 15.0 M | $170 M |